Merck (NYSE:MRK) plans to present more than 100 oncology abstracts at the 2026 ASCO Annual Meeting. The company will share ...

Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a ...

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety Feb ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock closed ...

Merck's biggest cash cow could soon face competition from two drugs in development. However, the company is working on ways to get around this potential headwind. These are all good things, none of ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck prepares to ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

Three hours inland from Chennai, India, traffic crawls on a half-finished road past rice fields and cow crossings until it reaches a newer complex of neat white buildings. Among them is the cancer ...